Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.43 |
| ▸ | ITGAV | P06756 | 20/20 | 0.43 |
| ▸ | ITGB6 | P18564 | 13/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.37 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.37 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.37 |
| ▸ | ITGB8 | P26012 | 2/20 | 0.37 |
| ▸ | ITGA8 | P53708 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6222502 | 0.76 | ITGB3 (0.73) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7449770 | 0.75 | ITGB3 (0.59) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7450003 | 0.68 | ITGB3 (0.60) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7347231 | 0.67 | LMNA (0.38) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL7347208 | 0.67 | SMN1; SMN2 (0.41) | ITGB3ITGAVITGB1ITGA5 | |
| SCHEMBL7340034 | 0.66 | LMNA (0.38) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7367982 | 0.66 | ITGB3 (0.38) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7346981 | 0.66 | SMN1; SMN2 (0.39) | ITGB3ITGAVITGB6 | |
| SCHEMBL7367429 | 0.64 | ITGB3 (0.62) | ITGB3ITGAVITGB6ITGB1ITGA5 | |
| SCHEMBL7349856 | 0.64 | ITGB3 (0.46) | ITGB3ITGAVITGB6ITGB1ITGA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | PHARMACIA CORPORATION | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020505-A1 | R-isomer of beta amino acid compounds as integrin receptor antagonists derivatives | ITGA5, ITGAL, ITGB5 | ITGB3 9/4885ITGAV 4/4885ITGB6 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.